Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Arte... (

Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease

Date:4/8/2008

- Findings Presented at the American College of Cardiology 57th Annual

Scientific Session -

FREMONT, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, presented data from a study providing further confirmation that the Company's multi-protein biomarker panel may aid in the diagnosis of peripheral artery disease (PAD). The research suggests that such a panel may be useful in alerting physicians to the possibility of PAD in patients who might otherwise be undiagnosed. Results of the study were presented as a poster at the American College of Cardiology 57th Annual Scientific Session.

Working in collaboration with researchers at Stanford University, Vermillion intends to develop a blood test for the diagnosis of PAD. In March, the Company entered into an exclusive license agreement with the University to develop and commercialize a biomarker panel used to assess the risk of the disease, which is estimated to affect up to 12 million Americans and can result in severe complications, including amputation, heart attack, stroke and even death.

"Few studies have explored combinations of protein markers to create a distinct biomarker panel score to stratify individuals according to their risk of having PAD. However, our study successfully accomplishes this by discovering a multi-marker panel that could significantly aid in identifying such patients," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer of Vermillion. "We are pleased with these findings and are developing a clinical trial protocol to generate data for support of a submission to the U.S. Food and Drug Administration (FDA)."

The study was conducted to develop an
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio

Post Your Comments:

Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Arte...( - Findings Presented at the Americ...)